| Ekim et al. 21
|
Group I - LLLT |
VAS |
10 sessions (2 weeks) |
Skin contact |
Region volar in the direction of median nerve |
19 patients with carpal tunnel syndrome caused by RA |
6 |
| Group II- placebo |
| Silva, Noravett, Baldan 31
|
Study Group- LLLT |
Br-MPQ Pain Questionnaire, Brazilian Version. |
10 sessions (5 weeks) |
Skin contact |
Region of pain´s reported. |
10 participants with RA |
7 |
| Control Group |
| Meireles et al. 27
|
Group I - LLLT |
VAS |
16 sessions (8weeks) |
Skin contact |
joint lines of wrist and fingers |
82 patients with RA. |
10 |
| Group II - Placebo |
|
Hands´ osteoarthritis
|
| Baltzer, Ostapczuk Stosch 25
|
No group |
VAS |
5 a 10 sessions (2,5 a 5 weeks) |
Skin contact |
Several points in the intra-articular space. |
34 patients with hand OA with Bouchard and Heberden signs. |
3 |
|
Knee´s osteoarthritis
|
| Yurtkuran et al. 14
|
Group Laser |
VAS; WOMAC |
10 sessions (2 weeks) |
Skin contact |
Lateral side of knee at acupuncture point Sp9 |
52 patients with knee OA. |
8 |
| Group Placebo |
| Hegedús et al. 32
|
Group Laser |
VAS |
8 sessions (4 weeks) |
Skin contact |
femoral and tibial condyles, articular line and fibular head |
27 patients with knee OA |
6 |
| Group Placebo |
| Zhao et al. 33
|
Group Laser |
WOMAC |
12 sessions (4 weeks) |
2 cm above skin |
joint line at the acupuncture point ST35 |
40 patients with knee OA |
8 |
| Group Placebo |
| Fukuda et al. 34
|
Group Laser |
VAS; Lequesne Scale |
9 sessions (3 weeks) |
Skin contact |
femoral and tibial condyles, articular line and fibular head |
47 patients with knee OA |
10 |
| Group Placebo |
| Štiglić-Rogoznica et al. 35
|
No group |
VAS |
10 sessions (10 days) |
Skin contact |
not supplied |
96 patients with knee OA |
3 |
| Gworys et al. 36
|
Group 1 laser irradiation Group 2 (MSL irradiation) Group 3 (MSL irradiation) Group 4 placebo |
Lequesne scale, VAS; Modified Laitinen questionnaire |
10 sessions (2 weeks) |
Skin contact |
femoral and tibial condyles, articular line and fibular head |
125 patients with knee OA |
9 |
| Kedzierski et al. 37
|
Group A - MSL laser therapy Group B - low frequency TENS. |
VAS; Modified Laitinen questionnaire. |
10 sessions (2 weeks) |
Skin contact |
Joint space, popliteal fossa and base of patella |
50 patients with knee OA |
5 |
| Rayegani et al. 38
|
Group 1 LLLT, Group 2 LLLT placebo; Group 3 Ultrasound. |
VAS; WOMAC |
10 sessions (2 weeks) |
Skin contact |
femoral and tibial condyles, articular line and fibular head |
37 patients with knee OA |
7 |
| Alghadir et al. 16
|
Group Laser |
VAS; WOMAC. |
8 sessions (4 weeks) |
Skin contact |
femoral and tibial condyles, articular line and fibular head |
40 patients with knee OA |
10 |
| Group Placebo |
| Nakamura et al. 39
|
No group |
VAS |
8 sessions (4 weeks) |
Skin contact |
Articular line |
35 patients with knee OA |
3 |
| Soleimanpour et al. 40
|
No group |
VAS |
12 sessions (4 weeks) |
Skin contact |
LASER I- around patella; LASER II- bellow patella. |
18 patients with knee OA |
3 |
| Hinman et al. 28
|
Control group, Group Needle acupuncture, Group laser |
VAS; WOMAC |
12 sessions (4 weeks) |
Skin contact |
Various acupuncture points |
282 patients with knee OA |
7 |
| Group placebo laser . |
| Nambi et al. 41
|
Group Laser |
VAS, joint space width, collagen-II telopeptide and MMP-3, 8, and 13 |
12 sessions (4 weeks) |
Skin contact |
Medial and lateral epicondyle of tibia and femur, tendon of the biceps femoris muscle and semitendinosus muscle |
34 patients with knee OA |
9 |
| Group Placebo |
| Nazari et al. 42
|
High-intensity laser therapy (HILT) group, conventional physical therapy (CPT) group, and exercise therapy (ET) group |
VAS, knee flexion range of motion, timed up and go test,6-min walk test, WOMAC |
12 sessions (4 weeks) |
Skin contact |
Articular line |
93 patients with knee OA |
7 |
|
Temporomandibular´s osteoarthritis
|
| Madani et al. 43
|
Group Laser |
VAS |
12 sessions (4 weeks) |
Skin contact |
Points around the temporomandibular joint, mandibular muscles and condyles. |
20 patients with temporomandibular OA |
8 |
| Group Placebo |